Verseon

Fremont, United States Founded: 2002 • Age: 24 yrs
Therapeutics are developed in oncology, ophthalmology, and cardiovascular areas.
Annual revenue - Latest available
Total funding $19.1M 7 rounds
Employees 60 Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors - Brand Intelligence

About Verseon

Verseon is a company based in Fremont (United States) founded in 2002 by Eniko Fodor. Verseon has raised $19.08 million across 7 funding rounds. The company has 60 employees as of December 31, 2022. Verseon has completed 1 acquisition, including Edammo.

  • Headquarter Fremont, United States
  • Employees 60 as on 31 Dec, 2022
  • Founders Eniko Fodor
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Verseon India Private Limited
  • Date of Incorporation 13 Mar, 2006
  • Jurisdiction Hyderabad, Telangana, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $19.08 M (USD)

    in 7 rounds

  • Latest Funding Round
    $101.4 K (USD), Post-IPO

    Apr 24, 2019

  • Investors
    Not available
  • Employee Count
    60

    as on Dec 31, 2022

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Verseon

Headcount 10-50
Employee Profiles 11
Employee Profiles
People
Adityo Prakash
Founder & CEO
People
Eniko Fodor
Founder & COO
People
David Kita
Founder & VP of R&D
People
Anirban Datta
Senior Director of Discovery Biology

Unlock access to complete

Funding Insights of Verseon

Verseon has successfully raised a total of $19.08M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $101.4 thousand completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by Verseon

Verseon has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Edammo.

Investments
Premium access

Investment portfolio details for Verseon

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Data analytics and consulting services are provided to clients.
Locked Locked 2016 Locked
Premium access

Complete acquisition details for Verseon

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Verseon

Premium access

Detailed financials for Verseon

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Verseon Comparisons

Verseon Primary company
Description
Therapeutics are developed in oncology, ophthalmology, and c...
Location
Fremont, United States
Founded Year
2002
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
60
As of 2022
Premium access

Peer comparison for Verseon

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Verseon

Premium access

Detailed competitors of Verseon

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Verseon

Premium access

Complete news archive for Verseon

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Verseon

Verseon was founded in 2002 and raised its 1st funding round 3 years after it was founded.

Verseon is headquartered in Fremont, United States. It is registered at Fremont, California, United States.

Verseon is a funded company, having raised a total of $19.08M across 7 funding rounds to date.

As of Dec 31, 2022, the latest employee count at Verseon is 60.

Verseon was founded in 2002 and is based in Fremont, United States, within the pharmaceutical sector. A drug discovery platform is utilized, relying on physics-based molecular modeling of protein-drug interactions and computational analysis to identify compounds for targets with known structures. The pipeline encompasses preclinical oral anticoagulants for anticoagulation, discovery-stage kallikrein inhibitors for diabetic macular edema, and angiogenesis inhibitors for solid tumors.

Verseon has made 1 acquisition, including Edammo.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available